Needham Maintains Buy on Neumora Therapeutics, Lowers Price Target to $5
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the price target from $8 to $5.
Needham analyst Ami Fadia maintains Neumora Therapeutics (NASDAQ:NMRA) with a Buy and lowers the price target from $8 to $5.